Skip to main navigation Skip to search Skip to main content

Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)e442-e445
JournalClinical Lung Cancer
Volume22
Issue number3
DOIs
StatePublished - May 2021

Keywords

  • Atypical lung carcinoid
  • Neuroendocrine tumor
  • RET
  • RET fusion
  • Targeted therapeutics

Cite this